ClinicalTrials.gg
CompletedNCT00240331Updated May 19, 2011Results posted

AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)

A Phase 3 interventional study of 10mg Rosuvastatin and Placebo in Renal Failure, sponsored by AstraZeneca. Completed at 241 sites in 25 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-05-19.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,776
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
Largest of 29
2,776 · median 24
Started
2003
the only one that year
Phase 3
2 of 29
none open now
Registered
1st of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one has the largest enrollment, is the only one that started in 2003, is one of 2 in phase 3, and was the 1st registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.

03

Conditions studied

  • Renal Failure

Keywords

  • End Stage Renal Failure
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with end-stage renal failure aged 50-80 years, who have received regular haemodialysis treatment for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Subjects will have no underlying condition that is expected to limit survival to less than 1 year and is also unrelated to end-stage renal disease (ESRD). Subjects should not have received a statin therapy within the past 6 months
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
2,776 participants (actual)

Study arms

  • Experimental
    Rosuvastatin 10mg

    Drug: 10mg Rosuvastatin

  • Placebo comparator
    Placebo

    matching Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)

    Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years

Secondary outcomes

  1. Number of Randomised Participants That Died From Any Cause.

    Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years

  2. Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause

    Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years

  3. Number of Randomised Participants That Died From Cardiovascular Cause

    Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years

  4. Number of Randomised Participants That Died From Non Cardiovascular Cause

    Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years

  5. Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death)

    Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years

  6. Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis.

    Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years

  7. Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations).

    Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years

07

Results

Posted Nov 4, 2009
Limitations and caveats
The endpoints were originally intended to be time to event endpoints, however we are unable to report the data as intended due to the nature of time to event endpoints. Therefore we have reported the number of participants who reached the event.

Participant flow

Recruited patients were male or female with end-stage renal failure aged 50 to 80 years, who had received regular chronic haemodialysis treatment (including haemofiltration and hemodiafiltration ) for at least 3 months. They were recruited from 280 sites in 25 countries; recruitment started on 16 January 2003 and finished on 24 November 2004.

Participant flow — Overall Study
MilestoneRosuvastatin 10mgPlacebo
Started13891384
Completed12631250
Not completed126134
Withdrew: Withdrawal by subject125132
Withdrew: Option selected by investigator12

Outcome measures

PrimaryNumber of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)
Time frame:
Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Reported as:
Number · Participants
Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)
ParticipantsRosuvastatin 10mgPlacebo
Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)396408
SecondaryNumber of Randomised Participants That Died From Any Cause.
Time frame:
Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Reported as:
Number · Participants
Number of Randomised Participants That Died From Any Cause.
ParticipantsRosuvastatin 10mgPlacebo
Number of Randomised Participants That Died From Any Cause.636660
SecondaryNumber of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause
Time frame:
Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Reported as:
Number · Participants
Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause
ParticipantsRosuvastatin 10mgPlacebo
Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause614645
SecondaryNumber of Randomised Participants That Died From Cardiovascular Cause
Time frame:
Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Reported as:
Number · Participants
Number of Randomised Participants That Died From Cardiovascular Cause
ParticipantsRosuvastatin 10mgPlacebo
Number of Randomised Participants That Died From Cardiovascular Cause324324
SecondaryNumber of Randomised Participants That Died From Non Cardiovascular Cause
Time frame:
Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Reported as:
Number · Participants

Results for this outcome have not been posted.

SecondaryNumber of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death)
Time frame:
Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Reported as:
Number · Participants
Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death)
ParticipantsRosuvastatin 10mgPlacebo
Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death)258256
SecondaryNumber of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis.
Time frame:
Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Reported as:
Number · Participants
Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis.
ParticipantsRosuvastatin 10mgPlacebo
Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis.390360
SecondaryNumber of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations).
Time frame:
Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Reported as:
Number · Participants
Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations).
ParticipantsRosuvastatin 10mgPlacebo
Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations).148152

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 10mg——620/1,389 (44.6%)
Placebo——635/1,378 (46.1%)
Most frequent serious events
Showing 10 of 915
Most frequent serious events
EventRosuvastatin 10mgPlacebo
PneumoniaInfections and infestations92/138996/1378
SepsisInfections and infestations65/138970/1378
Arteriovenous Fistula Site ComplicationInjury, poisoning and procedural complications54/138960/1378
Myocardial InfarctionCardiac disorders53/138952/1378
Arteriovenous Fistula ThrombosisInjury, poisoning and procedural complications53/138945/1378
Atrial FibrillationCardiac disorders39/138945/1378
Vascular Access ComplicationInjury, poisoning and procedural complications30/138940/1378
Cardiac FailureCardiac disorders30/138935/1378
Sudden DeathGeneral disorders33/138930/1378
Angina PectorisCardiac disorders21/138931/1378
Most frequent other events
Showing 10 of 24
Most frequent other events
EventRosuvastatin 10mgPlacebo
DiarrhoeaGastrointestinal disorders202/1389188/1378
BronchitisInfections and infestations129/1389133/1378
Arteriovenous Fistula Site ComplicationInjury, poisoning and procedural complications131/1389131/1378
VomitingGastrointestinal disorders112/1389127/1378
NasopharyngitisInfections and infestations127/1389116/1378
CoughRespiratory, thoracic and mediastinal disorders120/1389125/1378
NauseaGastrointestinal disorders121/138997/1378
HypotensionVascular disorders115/1389109/1378
HeadacheNervous system disorders109/1389112/1378
ArthralgiaMusculoskeletal and connective tissue disorders110/138993/1378

Baseline characteristics

Age Continuous
Age Continuous(Years)Rosuvastatin 10mgPlaceboTotal
Mean64.1 ± 8.664.3 ± 8.764.2 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 10mgPlaceboTotal
Female5385121050
Male8518721723
08

Study locations

241 sites
  • Research Site
    St Leonards, New South Wales, Australia
  • Research Site
    Herston, Queensland, Australia
  • Research Site
    Bregenz, Austria
  • Research Site
    Feldkirch-Tisis, Austria
  • Research Site
    Graz, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    Linz, Austria
  • Research Site
    St. Poelten, Austria
  • Research Site
    Wels, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Aalst, Belgium
  • Research Site
    Antwerpen, Belgium
  • Research Site
    Brussels, Belgium
  • Research Site
    La Louviere, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Liège, Belgium
  • Research Site
    Curitiba, PR, Brazil
  • Research Site
    Sao Paulo, SP, Brazil
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Plovdiv, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Lethbridge, Alberta, Canada
  • Research Site
    Kelowna, British Columbia, Canada
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Winnipeg, Manitoba, Canada
  • Research Site
    Saint John, New Brunswick, Canada
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    Mississauga, Ontario, Canada
  • Research Site
    Scarborough, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    York, Ontario, Canada
  • Research Site
    Greenfield Park, Quebec, Canada
  • Research Site
    Laval, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Trois-Rivieres, Quebec, Canada
  • Research Site
    Kitchener, Canada
  • Research Site
    Rosemount, Canada
  • Research Site
    Hodonin, Czech Republic
  • Research Site
    Hradec Kralove, Czech Republic
  • Research Site
    Liberec, Czech Republic
  • Research Site
    Pardubice, Czech Republic
  • Research Site
    Praha 2, Czech Republic
  • Research Site
    Praha 4, Czech Republic
  • Research Site
    Praha 6, Czech Republic
  • Research Site
    Tabor, Czech Republic
  • Research Site
    Usti nad Labem, Czech Republic
  • Research Site
    Fredericia, Denmark
  • Research Site
    Frederiksberg, Denmark
  • Research Site
    Herlev, Denmark
  • Research Site
    Holbaek, Denmark
  • Research Site
    Horsens, Denmark
  • Research Site
    København Ø, Denmark
  • Research Site
    Roskilde, Denmark
  • Research Site
    Rønne, Denmark
  • Research Site
    Slagelse, Denmark
  • Research Site
    Sønderborg, Denmark
  • Research Site
    Viborg, Denmark
  • Research Site
    Helsinki, Finland
  • Research Site
    Hyvinkaa, Finland
  • Research Site
    Joensuu, Finland
  • Research Site
    Kotka, Finland
  • Research Site
    Kuopio, Finland
  • Research Site
    Lahti, Finland
  • Research Site
    Oulu, Finland
  • Research Site
    Pori, Finland
  • Research Site
    Tammisaari, Finland
  • Research Site
    Tampere, Finland
  • Research Site
    Turku, Finland
  • Research Site
    Amiens, France
  • Research Site
    Annonay Cedex, France
  • Research Site
    Aubervilliers, France
  • Research Site
    Beauvais, France
  • Research Site
    Bethune Cedex, France
  • Research Site
    Boulogne Sur Mer, France
  • Research Site
    Chambery, France
  • Research Site
    Champigny Sur Marne, France
  • Research Site
    Colmar Cedex, France
  • Research Site
    Creil Cedex 1, France
  • Research Site
    Evreux Cedex, France
  • Research Site
    Fleury Merogis, France
  • Research Site
    Foix Cedex, France
  • Research Site
    Le Kremlin-Bicetre, France
  • Research Site
    Maubeuge, France
  • Research Site
    Meaux, France
  • Research Site
    Mont de Marsan Cedex, France
  • Research Site
    Montbonnot Saint Martin, France
  • Research Site
    Nimes, France
  • Research Site
    Olivet, France
  • Research Site
    Paris, France
  • Research Site
    Quimper Cedex, France
  • Research Site
    Saint Maurice, France
  • Research Site
    Saint Michel, France
  • Research Site
    Tournan En Brie, France
  • Research Site
    Valenciennes Cedex, France
  • Research Site
    Vandoeuvre Les Nancy, France
  • Research Site
    Vichy, France
  • Research Site
    Ansbach, Germany

Showing the first 100 of 241 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. Erratum In: N Engl J Med. 2010 Apr 15;362(15):1450. PubMed 19332456 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2005
First posted
Oct 18, 2005
Start
Jan 2003
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Nov 4, 2009
Last update
May 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00240331
Lead sponsor
AstraZeneca
First posted
Oct 18, 2005
Start date
Jan 2003
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Nov 4, 2009
Last update
May 19, 2011

Study contacts

AstraZeneca Crestor Medical Sciences Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion